Showing session: reset
Promising Trials in Immunotherapy
- Sort by:
- Browse by:
- Free
- slides video
- audio + slides
- All slides included
Clinical safety and efficacy of pembrolizumab (MK-3475) in patients with malignant pleural mesothelioma: Preliminary results from KEYNOTE-028
Evan W Alley
University of Pennsylvania, Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Efficacy of pembrolizumab (MK-3475) and relationship with PD-L1 expression in patients with non-small cell lung cancer: Findings from KEYNOTE-001)
Edward B. Garon
David Geffen School of Medicine at UCLA, Los Angeles, CA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
D. Ross Camidge
University of Colorado Denver, Aurora, CO, United States
- Free
- slides video
- audio + slides
- All slides included
Safety and feasibility of chimeric antigen receptor modified T cells directed against mesothelin (CART-meso) in patients with mesothelin expressing cancers
Janos L Tanyi
Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Michel Sadelain
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
A phase I/IIa study of IMCgp100: Partial and complete durable responses with a novel first-in-class immunotherapy for advanced melanoma
Mark R Middleton
University of Oxford, Oxford, United Kingdom
- Free
- slides video
- audio + slides
- All slides included
Epstein-Barr virus-specific cytotoxic T lymphocytes for treatment of rituximab-refractory Epstein-Barr virus-associated lymphoproliferative disorder
Susan E Prockop
Memorial Sloan Kettering Cancer Center, New York, NY, United States
- Free
- slides video
- audio + slides
- All slides included
Discussant
Antoni Ribas
UCLA Medical Center, Los Angeles, CA, United States